Pharmaceuticals & Medical Devices (Healthcare/Life Sciences)
Strategic Profile
J&J has double-digit growth potential by decade's end, underpinned by a diversified base of 28 billion-dollar products and rapid expansion in oncology, immunology, and cardiovascular markets. The company recently announced its 63rd consecutive annual dividend increase, maintaining its prestigious title as a Dividend King.
Cyborg Score Rationale
Johnson & Johnson reported 7.1% quarterly operational sales growth with accelerated momentum in both Innovative Medicine and MedTech segments. The company forecast 2026 operational sales of $99.5 billion to $100.5 billion, exceeding analysts' estimates of $98.9 billion. Operating margins of 27% anchor the company's ability to fund R&D while absorbing policy and pricing pressure.
Top Insights
Significant pipeline innovation includes approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, with landmark data for TECVAYLI plus DARZALEX FASPRO as potential standard of care
Company invested $32 billion in R&D and M&A during 2025, including strategic acquisitions of Intra-Cellular Therapies and Halda Therapeutics
J&J navigated hundreds of millions in drug pricing impact from Trump administration deal while still exceeding guidance, demonstrating operational resilience
MedTech momentum accelerated in February 2026 with OMNY-AF pilot results showing 90% primary effectiveness at 12 months with 0% adverse event rate
Named Competitors
Innovative Medicines — Competing pharmaceutical innovator across oncology and immunology
Merck Medicines — Leading pharmaceutical competitor in oncology and vaccines
Medical Devices — Major competitor in cardiovascular and surgical device markets
AbbVie Medicines — Pharmaceutical competitor focusing on immunology and oncology
Recent Developments
(February 2026) OMNY-AF pilot demonstrates 90% effectiveness at 12 months, strengthening pulsed-field ablation market position
(January 2026) Issued 2026 guidance with $100.5 billion sales and $11.53 adjusted EPS at midpoint, exceeding analyst expectations
(January 2026) Managed drug pricing deal impact while forecasting above-consensus growth in revenue and earnings
(2025) Closed acquisitions of Intra-Cellular Therapies and Halda Therapeutics as part of $32 billion strategic investment
Open the full interactive Johnson & Johnson report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.